Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.75 (overall 0.47) | 0.75 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in choroid plexus epithelial cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 29 | 0.73 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
Knock down and overexpress SLC2A13 in dopamine neurons; measure a transcriptome-wide state shift (bulk RNA-seq) and survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils.
- Cell type
- dopamine neurons
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- a transcriptome-wide state shift (bulk RNA-seq)
- Functional readout
- survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils
- Rule-out
- If neither arm moves a transcriptome-wide state shift (bulk RNA-seq) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of SLC2A13 in iPSC-derived midbrain dopamine neurons (FOXA2+, LMX1A+, TH+); n = 3 differentiations; readouts: a transcriptome-wide state shift (bulk RNA-seq); survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- SLC2A13 in dopamine neurons, braak+0.52 (p 0.148) → +0.62 (p 0.074)receipt 0311
Swarm cases
receipt 0311: SLC2A13 in dopamine neurons, braak
- power
- full sample +0.48 (p 0.042, n 18), 95% CI +0.02 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.47 (p 0.050, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.044, n 18). not the mix.
- skeptic
- leave-one-out range +0.42 to +0.67, sign flips 0; without severely affected donors +0.48 (p 0.042, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC2A13 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts